Literature DB >> 18801404

Opioid maintenance therapy suppresses alcohol intake in heroin addicts with alcohol dependence: preliminary results of an open randomized study.

Felice Nava1, Ezio Manzato, Claudio Leonardi, Alfio Lucchini.   

Abstract

An open randomized study lasting 12 months was performed to evaluate the efficacy of methadone or buprenorphine to suppress alcohol use in two hundred and eighteen heroin addicts with alcohol dependence. Daily maintenance doses of methadone were 80, 120, 160, and 200 mg/day, while doses of buprenorphine were 8, 16, 24, and 32 mg/day. As expected, both treatments were able to reduce both heroin use and addiction severity (measured with ASI interview). However, although both medications were able to suppress alcohol use, the highest dose of buprenorphine was better than the highest dose of methadone, in reducing alcohol craving, ethanol intake (measured as daily number of drinks), and the ASI subscale of alcohol use. The mechanism underlying the effects of the opioid maintenance therapy on the reduction of alcohol intake is still unclear. The results of the present study may represent the first clinical evidence of the potential effective use of the highest doses of buprenorphine for the suppression of ethanol intake in heroin addicts with alcohol dependence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18801404     DOI: 10.1016/j.pnpbp.2008.08.019

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  10 in total

1.  Problem drinking and low-dose naltrexone-assisted opioid detoxification.

Authors:  Paolo Mannelli; Kathleen Peindl; Ashwin A Patkar; Li-Tzy Wu; Haresh M Tharwani; David A Gorelick
Journal:  J Stud Alcohol Drugs       Date:  2011-05       Impact factor: 2.582

2.  Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection.

Authors:  Jeanette M Tetrault; Janet P Tate; E Jennifer Edelman; Adam J Gordon; Vincent Lo Re; Joseph K Lim; David Rimland; Joseph Goulet; Stephen Crystal; Julie R Gaither; Cynthia L Gibert; Maria C Rodriguez-Barradas; Lynn E Fiellin; Kendall Bryant; Amy C Justice; David A Fiellin
Journal:  J Subst Abuse Treat       Date:  2016-06-06

Review 3.  The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.

Authors:  Nurulain T Zaveri
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

Review 4.  Translational approach to develop novel medications on alcohol addiction: focus on neuropeptides.

Authors:  Massimo Ubaldi; Angelo Bifone; Roberto Ciccocioppo
Journal:  Curr Opin Neurobiol       Date:  2013-05-03       Impact factor: 6.627

Review 5.  The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.

Authors:  Jeffrey M Witkin; Michael A Statnick; Linda M Rorick-Kehn; John E Pintar; Michael Ansonoff; Yanyun Chen; R Craig Tucker; Roberto Ciccocioppo
Journal:  Pharmacol Ther       Date:  2013-11-01       Impact factor: 12.310

6.  Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.

Authors:  John D Roache; Martina Pavlicova; Aimee Campbell; Tse-Hwei Choo; Michelle Peavy; Andrea S Kermack; Edward V Nunes; John Rotrosen
Journal:  Alcohol Clin Exp Res       Date:  2021-11-23       Impact factor: 3.455

Review 7.  Alcohol use in opioid agonist treatment.

Authors:  Seonaid Nolan; Jan Klimas; Evan Wood
Journal:  Addict Sci Clin Pract       Date:  2016-12-08

8.  Prevalence of Coaddictions and Rate of Successful Treatment Among a French Sample of Opioid-Dependent Patients With Long-Term Opioid Substitution Therapy: The OPAL Study.

Authors:  Marie Grall-Bronnec; Edouard-Jules Laforgue; Gaëlle Challet-Bouju; Jennyfer Cholet; Jean-Benoit Hardouin; Juliette Leboucher; Morgane Guillou-Landréat; Caroline Victorri-Vigneau
Journal:  Front Psychiatry       Date:  2019-10-17       Impact factor: 4.157

Review 9.  Role of Nociceptin/Orphanin FQ-NOP Receptor System in the Regulation of Stress-Related Disorders.

Authors:  Massimo Ubaldi; Nazzareno Cannella; Anna Maria Borruto; Michele Petrella; Maria Vittoria Micioni Di Bonaventura; Laura Soverchia; Serena Stopponi; Friedbert Weiss; Carlo Cifani; Roberto Ciccocioppo
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 6.208

10.  An examination between treatment type and treatment retention in persons with opioid and co-occurring alcohol use disorders.

Authors:  Carrie M Mintz; Ned J Presnall; Kevin Y Xu; Sarah M Hartz; John M Sahrmann; Laura J Bierut; Richard A Grucza
Journal:  Drug Alcohol Depend       Date:  2021-06-25       Impact factor: 4.852

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.